Perilous Reversal Stock: Bluebird Bio (BLUE)
Trade-Ideas LLC identified
(
) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified bluebird bio as such a stock due to the following factors:
- BLUE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $168.3 million.
- BLUE has traded 140,708 shares today.
- BLUE is down 3.4% today.
- BLUE was up 6.3% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BLUE with the Ticky from Trade-Ideas. See the FREE profile for BLUE NOW at Trade-Ideas
More details on BLUE:
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Currently there are 12 analysts that rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for bluebird bio has been 1.4 million shares per day over the past 30 days. Bluebird bio has a market cap of $2.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.78 and a short float of 13.4% with 1.50 days to cover. Shares are down 7.8% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates bluebird bio as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity.
Highlights from the ratings report include:
- BLUEBIRD BIO INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, BLUEBIRD BIO INC reported poor results of -$1.78 versus -$0.80 in the prior year. For the next year, the market is expecting a contraction of 163.2% in earnings (-$4.69 versus -$1.78).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 152.1% when compared to the same quarter one year ago, falling from -$17.03 million to -$42.93 million.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, BLUEBIRD BIO INC's return on equity significantly trails that of both the industry average and the S&P 500.
- BLUE, with its very weak revenue results, has greatly underperformed against the industry average of 13.4%. Since the same quarter one year prior, revenues plummeted by 79.2%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- Compared to its closing price of one year ago, BLUE's share price has jumped by 76.23%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in BLUE do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full bluebird bio Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.